Hypermarcas (OTCMKTS:HYPMY) Shares Cross Below Fifty Day Moving Average – What’s Next?

Shares of Hypermarcas (OTCMKTS:HYPMY) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $4.42 and traded as low as $4.39. Hypermarcas shares last traded at $4.40, with a volume of 1,819 shares.

Wall Street Analyst Weigh In

Separately, Scotiabank raised shares of Hypermarcas to a “strong-buy” rating in a research report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, Hypermarcas currently has a consensus rating of “Strong Buy”.

Hypermarcas Trading Down 1.1%

The company has a market cap of $2.79 billion, a price-to-earnings ratio of 20.95 and a beta of 0.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The business’s 50 day moving average price is $4.42 and its 200-day moving average price is $4.22.

Hypermarcas (OTCMKTS:HYPMY) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.